ArticleAACE endocrinology and diabetes
Alogliptin-Pioglitazone and Insulin Regimen for Inpatient Glycemic Control: A Randomized Continuous Glucose Monitoring Pilot Trial.
Article in AACE endocrinology and diabetes. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Hospitalized patients with type 2 diabetes (T2D) frequently develop hyperglycemia, hypoglycemia, and glycemic variability, which are associated with adverse outcomes outside the intensive care unit. This pilot randomized controlled trial evaluated whether adding a fixed-dose combination (FDC) of alogliptin/pioglitazone to standard basal-bolus insulin improved time in range (TIR), reduced hypoglycemia and/or bolus insulin requirements versus placebo, while generating effect size estimates for a future multicenter trial. Methods: In this randomized, double-blind, placebo-controlled pilot study, the placebo group ( Results: The IG achieved significantly higher TIR than placebo (72.44% vs 38.58%; Conclusions: In this highly selected inpatient population, adjunctive alogliptin/pioglitazone added to basal-bolus insulin improved continuous glucose monitoring-derived glycaemic stability. Larger adequately powered multicentre trials are needed to confirm safety and efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.